[Clinical Evaluation of Indoleamine 2, 3-Dioxygenase in the Serum of Patients with Locally Advanced Breast Cancer during Mohs Paste Treatment].
Locally advanced breast cancer lesions often compromise patients' quality of life(QOL). Mohs paste is a histopathological fixative with zinc chloride as the main ingredient. It is applied when performing chemosurgery for skin tumors. In recent years, this paste has reportedly been very effective for the control of various symptoms of skin metastases in inoperable advanced cancers, such as pungent odor and hemorrhage, in the field of palliative care. We evaluated the clinical significance of indoleamine 2, 3-dioxygenase(IDO)in the serum of patients with locally advanced breast cancer during Mohs paste treatment. IDO activity was measured by the tryptophan(Trp)/kynurenine(Kyn)ratio. Trp and Kyn levels were measured using high performance liquid chromatography(HPLC). We collected serum samples from 3 locally advanced breast cancer cases: once in the pre-treatment phase, 2 times in the post-treatment phase, and 5 times in the post-treatment phase. Then, we measured the Trp/Kyn ratio and CRP in these samples during Mohs paste treatment. There were no significant differences in serum Trp/ Kyn ratios between the phases, but serum CRP values decreased after Mohs paste treatment. These results suggest that Mohs paste treatment for locally advanced breast cancer lesions may be useful in enhancing patients' QOL without immunosuppression.